Comparison of [111In]pentetreotide-SPECT and [ 18F]FDOPA-PET in the localization of extra-adrenal paragangliomas: The case for a patient-tailored use of nuclear imaging modalities

Clinical Endocrinology

Volumn 74, Issue 1, 2011, Pages 21-29

  Charrier, N ^a   Deveze, A ^b   Fakhry, N ^a   Sebag, F ^a   Morange, I ^a   Gaborit, B ^b   Barlier, A ^c   Carmona, E ^c   De Micco, C ^a   Garcia, S ^b   Mancini, J ^a,d   Palazzo, F F ^a   Lavieille, J P ^b   Zanaret, M ^a   Henry, J F ^a   Mundler, O ^a   Taieb D ^a  

^a TIMONE HOSPITAL   (France)

^b HÔPITAL NORD   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

^d AIX MARSEILLE UNIV   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORO LEVO 3,4 DIHYDROXYPHENYLALALANINE F 18; FLUORODEOXYGLUCOSE F 18; IASODOPA; METADRENALIN; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SUCCINATE DEHYDROGENASE (UBIQUINONE); UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DRUG DERIVATIVE; PENTETREOTIDE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

ABDOMINAL CANCER; ADULT; ARTICLE; CANCER SIZE; CLINICAL ARTICLE; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG UPTAKE; FAMILY HISTORY; FEMALE; GENE MUTATION; HEAD AND NECK CANCER; HORMONE RELEASE; HUMAN; MALE; PARAGANGLIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ADOLESCENT; AGED; CHEMODECTOMA; METABOLISM; METHODOLOGY; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; PARAGANGLIOMA, EXTRA-ADRENAL; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YOUNG ADULT;

EID: 78650369777     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2010.03893.x     Document Type: Article

References (40)

1. Lee, K.Y., Oh, Y.W., Noh, H.J., et al. (2006) Extraadrenal paragangliomas of the body: imaging features. American Journal of Roentgenology, 187, 492-504.
2. Timmers, H.J., Kozupa, A., Eisenhofer, G., et al. (2007) Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. Journal of Clinical Endocrinology and Metabolism, 92, 779-786.
3. Ilias, I., &, Pacak, K., (2004) Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 89, 479-491.
4. Bakker, W.H., Krenning, E.P., Breeman, W.A., et al. (1991) In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man. Journal of Nuclear Medicine, 32, 1184-1189.
5. Duet, M., Sauvaget, E., Petelle, B., et al. (2003) Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. Journal of Nuclear Medicine, 44, 1767-1774.
6. Erickson, D., Kudva, Y.C., Ebersold, M.J., et al. (2001) Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. Journal of Clinical Endocrinology and Metabolism, 86, 5210-5216.
7. Koopmans, K.P., Jager, P.L., Kema, I.P., et al. (2008) 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. Journal of Nuclear Medicine, 49, 1232-1237.
8. Krenning, E.P., Bakker, W.H., Breeman, W.A., et al. (1989) Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet, 1, 242-244.
9. Krenning, E.P., Bakker, W.H., Kooij, P.P., et al. (1992) Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. Journal of Nuclear Medicine, 33, 652-658.
10. Krenning, E.P., Kwekkeboom, D.J., Bakker, W.H., et al. (1993) Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. European Journal of Nuclear Medicine, 20, 716-731.
11. Kwekkeboom, D., Krenning, E.P., &, de Jong, M., (2000) Peptide receptor imaging and therapy. Journal of Nuclear Medicine, 41, 1704-1713.
12. Kwekkeboom, D.J., Lamberts, S.W., Habbema, J.D., et al. (1996) Cost-effectiveness analysis of somatostatin receptor scintigraphy. Journal of Nuclear Medicine, 37, 886-892.
13. Kwekkeboom, D.J., van Urk, H., Pauw, B.K., et al. (1993) Octreotide scintigraphy for the detection of paragangliomas. Journal of Nuclear Medicine, 34, 873-878.
14. Lamberts, S.W., Krenning, E.P., &, Reubi, J.C., (1991) The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Reviews, 12, 450-482.
15. Maurea, S., Cuocolo, A., Reynolds, J.C., et al. (1993) Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. Journal of Nuclear Medicine, 34, 173-179.
16. Muros, M.A., Llamas-Elvira, J.M., Rodriguez, A., et al. (1998) 111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma. Nuclear Medicine Communications, 19, 735-742.
17. Reubi, J.C., (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocrine Reviews, 24, 389-427.
18. Tenenbaum, F., Lumbroso, J., Schlumberger, M., et al. (1995) Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. Journal of Nuclear Medicine, 36, 1-6.
19. Whiteman, M.L., Serafini, A.N., Telischi, F.F., et al. (1997) 111In octreotide scintigraphy in the evaluation of head and neck lesions. American Journal of Neuroradiology, 18, 1073-1080.
20. Reubi, J.C., Waser, B., Khosla, S., et al. (1992) In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. Journal of Clinical Endocrinology and Metabolism, 74, 1082-1089.
21. Hofland, L.J., Liu, Q., Van Koetsveld, P.M., et al. (1999) Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. Journal of Clinical Endocrinology and Metabolism, 84, 775-780.
22. van Houtum, W.H., Corssmit, E.P., Douwes Dekker, P.B., et al. (2005) Increased prevalence of catecholamine excess and phaeochromocytomas in a well-defined Dutch population with SDHD-linked head and neck paragangliomas. European Journal of Endocrinology, 152, 87-94.
23. Brink, I., Schaefer, O., Walz, M., et al. (2006) Fluorine-18 DOPA PET imaging of paraganglioma syndrome. Clinical Nuclear Medicine, 31, 39-41.
24. Fanti, S., Ambrosini, V., Tomassetti, P., et al. (2008) Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. Biomedicine and pharmacotherapy, 62, 667-671.
25. Fottner, C., Helisch, A., Anlauf, M., et al. (2010) 6-18F-fluoro-L- dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. Journal of Clinical Endocrinology and Metabolism, 95, 2800-2810.
26. Havekes, B., King, K., Lai, E.W., et al. (2010) New imaging approaches to phaeochromocytomas and paragangliomas. Clinical Endocrinology. 72, 137-145.
27. Hoegerle, S., Ghanem, N., Altehoefer, C., et al. (2003) 18F-DOPA positron emission tomography for the detection of glomus tumours. European Journal of Nuclear Medicine and Molecular Imaging, 30, 689-694.
28. Hoegerle, S., Nitzsche, E., Altehoefer, C., et al. (2002) Pheochromocytomas: detection with 18F DOPA whole body PET-initial results. Radiology, 222, 507-512.
29. Ilias, I., Yu, J., Carrasquillo, J.A., et al. (2003) Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]- metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 88, 4083-4087.
30. Luster, M., Karges, W., Zeich, K., et al. (2010) Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma. European Journal of Nuclear Medicine and Molecular Imaging, 37, 484-493.
31. Taieb, D., Sebag, F., Barlier, A., et al. (2009) 18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature? Journal of Nuclear Medicine, 50, 711-717.
32. Taieb, D., Tessonnier, L., Sebag, F., et al. (2008) The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Clinical Endocrinology, 69, 580-586.
33. Timmers, H.J., Chen, C.C., Carrasquillo, J.A., et al. (2009) Comparison of 18F-Fluoro-L-DOPA, 18F-Fluoro-Deoxyglucose, and 18F-Fluorodopamine PET and 123I-MIBG Scintigraphy in the Localization of Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 94, 4757-4767.
34. Timmers, H.J., Eisenhofer, G., Carrasquillo, J.A., et al. (2009) Use of 6-[18F]-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO). Clinical Endocrinology, 71, 11-17.
35. Timmers, H.J., Kozupa, A., Chen, C.C., et al. (2007) Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. Journal of Clinical Oncology, 25, 2262-2269.
36. Wiseman, G.A., Pacak, K., O'Dorisio, M.S., et al. (2009) Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. Journal of Nuclear Medicine, 50, 1448-1454.
37. Dullaart, R.P., van der Horst-Schrivers, A.N., &, Koopmans, K.P., (2010) New imaging approaches to phaeochromocytomas and paragangliomas. Clinical Endocrinology, 72, 568-569; author reply 569.
38. Havekes, B., King, K., Lai, E.W., et al. (2010) New imaging approaches to phaeochromocytomas and paragangliomas. Clinical Endocrinology, 72, 137-145.
39. Kirov, A.S., Piao, J.Z., &, Schmidtlein, C.R., (2008) Partial volume effect correction in PET using regularized iterative deconvolution with variance control based on local topology. Physics in Medicine and Biology, 53, 2577-2591.
40. Reubi, J.C., Waser, B., Liu, Q., et al. (2000) Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. Journal of Clinical Endocrinology and Metabolism, 85, 3882-3891.